Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soligenix Inc (NQ: SNGX )

3.325 +0.003 (+0.09%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soligenix Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Soligenix Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Soligenix (NASDAQ:SNGX) posted sales of $400 thousand. Earnings were up 45.12%, but Soligenix still reported an overall loss of $2.39 million. 
Via Benzinga
Could This Company's HyBryte™ Provide A Safer, More Convenient Alternative To Cutaneous T-Cell Lymphoma Treatment?
Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being cured. 
Via Benzinga
Recap: Soligenix Q2 Earnings
  Soligenix (NASDAQ:SNGX) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
Recap: Soligenix Q4 Earnings
  Soligenix (NASDAQ:SNGX) reported its Q4 earnings results on Tuesday, March 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Soligenix's HyBryte Treatment Now Within Reach for Rare Cancer Patients
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
  
Via Benzinga
Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study
The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients... 
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Soligenix, Inc. (NASDAQ: SNGX) Developing Treatments for Multiple Cancers, Vaccine Candidates (Ebola, Sudan, & Marburg)
Via Get News
Exposures COVID-19
Developing Treatments for Multiple Cancers; Vaccine Candidates (Ebola, Sudan, and Marburg) Plus a Novel Heat Stable COVID-19 & Ricin Toxin Vaccines: Soligenix, Inc. (NASDAQ: SNGX)
Via Viz Release
Exposures COVID-19
Stocks That Hit 52-Week Lows On Friday
On Friday, 153 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 213 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 31.0% to $1.31 during Thursday's pre-market session. The company's market cap stands at $36.7 million.... 
Via Benzinga
Soligenix, Inc. (NASDAQ: SNGX) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
Via Investor Brand Network
Soligenix, Inc. (NASDAQ: SNGX) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
Via CryptoCurrencyWire
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.